L3Harris Technologies Receives 7-Year, $4.7B Lockheed Martin Contract To Produce Propulsion Systems For PAC-3 Missile Segment Enhancement Interceptor

Better Space Stock: AST SpaceMobile vs. L3Harris Technologies

AST SpaceMobile and L3Harris Technologies are compared as space industry investment options. AST SpaceMobile offers triple-digit revenue growth but faces execution risks, heavy cash burn, and equity dilution concerns. L3Harris is a mature defense contractor with predictable cash flows, a $42 billion backlog, and strong government contracts, but carries high debt and capital expansion risks. L3Harris appears the more stable choice despite lower growth rates.

LUNR Falls 46.4% in 3 Months. Is the Sell-Off a Buying Opportunity?

Intuitive Machines (LUNR) has declined 46.4% over three months despite achieving a record $1.8B backlog and booking $920M in Q2 2026 awards. While the company shows strong operational expansion with 70+ IM-300 spacecraft under contract and improving satellite production, it faces headwinds from fixed-price lunar mission risks, negative adjusted EBITDA, and a premium valuation multiple relative to peers. The stock carries a Hold rating with weak value, growth, and momentum scores, suggesting investors should await execution improvements rather than treating the decline as a buying opportunity.

Is LUNR Worth Buying as Growth Accelerates but Valuation Stays Rich?

Intuitive Machines (LUNR) reported Q2 revenues of $206.2 million, up 310% year-over-year, with a record $1.8 billion backlog and diversified revenue streams across civil, commercial, and national security sectors. However, the stock trades at a premium valuation (3.15X forward sales vs. 2.38X sub-industry average) while the company remains unprofitable, faces cash burn of $59.8 million quarterly, and has margin risks from fixed-price contracts. Analysts maintain a Hold rating, suggesting investors await better execution visibility before aggressive entry.

Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $94

LeMaitre Vascular shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 GAAP EPS and FY2026 sales guidance.

8-K filing — LEMAITRE VASCULAR INC (LMAT)

Filed: 2026-08-04 AccNo: 0001193125-26-332982 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits